Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $12.37 + 0.10 (0.00%)
ExchangeNASDAQ
Volume19,057
Today's Open$12.27
Previous Close$12.37
Data as of 07/20/17 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $12.37 with a 52 week high of $15.00 and a 52 week low of $4.63.

Recent News

June 21, 2017

Nuvectra Files Regulatory Submission with FDA for Algovita® MRI-Conditional Approval

PLANO, Texas, June 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MRI-conditional approval for the Company’s Algovita SCS system. Scott Drees, Chief Executive Officer, commented, “This submission to the FDA represents our continued commitment to the advancement of the Algovita system. The addition of a full bo

Read More >

May 09, 2017

Nuvectra™ Reports First Quarter 2017 Financial Results

PLANO, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2017. Highlights Record total revenues of $5.0 million, including total Algovita sales of $3.4 million U.S. commercial team building momentum with new and existing customers Remain on track with the Virtis U.S. and European regulatory approval timelines Scott Drees, CEO, said, “We c

Read More >


Investor Contact

The Ruth Group
Nick Laudico
Brian Johnston
investors@nuvectramed.com

Events
There are currently no events scheduled.